isabelobrien, Author at European Medical Journal - Page 49 of 66

Access win for HIV patients in sub-Saharan Africa

The injectable HIV treatment cabotegravir is set to become more widely available in sub-Saharan Africa following a new licensing agreement.

The Sunshine Rule: 5 years on

The Sunshine Rule swept away the clouds that cast shade over the pharmaceutical industry’s interactions with its customers, but what has been its impact five years on?

Sanofi lights ‘Beacon of Hope’ in race for greater diversity

Sanofi has joined the ‘Beacon of Hope’ programme – a Novartis initiative seeking to address racial inequality in clinical trials, health and education and to create greater diversity across R&D structures.

Sanofi Genzyme’s Bill Sibold on preventing future health inequities

Sanofi’s Bill Sibold shares his tips on reducing time to market for pharmaceutical drugs, public perceptions of the industry after COVID-19 and more.

ABPI wins prestigious PIF TICK status

The Association of the British Pharmaceutical Industry (ABPI) has been awarded PIF TICK trusted healthcare information creator status by the Patient Information Forum, in recognition of its commitment to providing clear, accurate information for patients and the public

Global health agencies collaborate to ease Ebola outbreak

CEPI, Gavi and WHO have announced a collective effort to support the Ugandan Government’s response to the recent Ebolavirus outbreak.

Access to medicine in Latin America

Track the access landscape in Latin America by examining medicine spending over the last five years and standout examples of ongoing initiatives founded by pharmaceutical companies to improve access in the region.

GSK’s John Wahba on the evolution of medical affairs

John Wahba, Medical Head of the Global Digital Hub, GSK, talks about how collaboration and teamwork will drive change in pharma, his views on digital and omnichannel optimisation and his passion for patient empowerment

Improving R&D pipeline projections

This infographic examines how the pharmaceutical industry’s R&D pipeline is evolving, looking at the companies leading the way and factors behind the recent uptick in IRR.

R&D progress on the rise

Pharmaceutical R&D saw sustained growth in clinical trial activity and a record number of novel active substances launched in 2021, according to a new report from IQVIA.